Activation of deoxycytidine kinase by protein kinase inhibitors and okadaic acid in leukemic cells

Biochemical Pharmacology

Volumn 68, Issue 1, 2004, Pages 95-103

  Smal, Caroline ^a   Cardoen, Sabine ^a   Bertrand, Luc ^a   Delacauw, Anne ^a   Ferrant, Augustin ^b   Van Den Berghe, Georges ^a   Neste, Eric Van Den ^a,b   Bontemps, Françoise ^a  

^a DE DUVE INSTITUTE   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

2 chloro 2 deoxyadenosine; B cell chronic lymphocytic leukemia; B CLL; CdA; dCK; deoxycytidine kinase; ERK; extracellular signal regulated kinase; JAK; Janus kinase; MAPK; mitogen activated protein kinase; OA; okadaic acid; PI 3 kinase

Indexed keywords

1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; 1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; CLADRIBINE; DEOXYCYTIDINE KINASE; GENISTEIN; JANUS KINASE; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; OKADAIC ACID; PHOSPHOPROTEIN PHOSPHATASE 1; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN KINASE INHIBITOR; STAUROSPORINE;

ARTICLE; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; INCUBATION TIME; LEUKEMIA CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANTINEOPLASTIC AGENTS; CARRIER PROTEINS; CLADRIBINE; DEOXYCYTIDINE KINASE; ENZYME ACTIVATION; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA; MITOGEN-ACTIVATED PROTEIN KINASES; OKADAIC ACID; PHOSPHOPROTEIN PHOSPHATASE; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; TUMOR CELLS, CULTURED;

EID: 2942627604     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2004.02.031     Document Type: Article

References (50)

1. Arner E.S.J., Eriksson S. Mammalian deoxyribonucleoside kinases. Pharmacol. Ther. 67:1995;155-186
2. Plunkett W, Gandhi V. Nucleoside analogs: cellular pharmacology, mechanisms of action, and strategies for combination therapy. In: Cheson BD, Keating MJ, Plunkett W, editors. Nucleoside analogs in cancer therapy. New York: Marcel-Dekker; 1997. p. 1-35.
3. Galmarini C.M., Mackey J.R., Dumontet C. Nucleoside analogues and nucleobases in cancer treatment. Lancet. Oncol. 3:2002;415-424
4. Johnson M.A., Johns D.G., Fridland A. 2′, 3′- Dideoxynucleoside phosphorylation by deoxycytidine kinase from normal human thymus extracts: activation of potential drugs for AIDS therapy. Biochem. Biophys. Res. Commun. 148:1987;1252-1258
5. Kewn S., Veal G.J., Hoggard P.G., Barry M.G., Back D.J. Lamivudine (3TC) phosphorylation and drug interactions in vitro. Biochem. Pharmacol. 54:1997;589-595
6. Kessel D., Hall T.C., Wodinsky I. Transport and phosphorylation as factors in the antitumor action of cytosine arabinoside. Science. 156:1967;1240-1241
7. Orr R.M., Talbot D.C., Wynne Aherne G., Fisher T.C., Serafinowski P., Harrap K.R. 2′-Deoxycytidine kinase deficiency is a major determinant of 2-chloro-2′-deoxyadenosine resistance in lymphoid cell lines. Clin. Cancer Res. 1:1995;391-398
8. Dumontet C., Fabianowska-Majewska K., Mantincic D., Callet Bauchu E., Tigaud I., Gandhi V., et al. Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562. Br. J. Haematol. 106:1999;78-85
9. Galmarini C.M., Mackey J.R., Dumontet C. Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia. 15:2001;875-890
10. Tattersall M.H., Ganeshaguru K., Hoffbrand A.V. Mechanisms of resistance of human acute leukaemia cells to cytosine arabinoside. Br. J. Haematol. 27:1974;39-46
11. Kawasaki H., Carrera C.J., Piro L.D., Saven A., Kipps T.J., Carson D.A. Relationship of deoxycytidine kinase and cytoplasmic 5′-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood. 81:1993;597-601
12. Arner E.S. On the phosphorylation of 2-chlorodeoxyadenosine (CdA) and its correlation with clinical response in leukemia treatment. Leuk. Lymphoma. 21:1996;225-231
13. Veuger M.J., Honders M.W., Landegent J.E., Willemze R., Barge R.M. High incidence of alternatively spliced forms of deoxycytidine kinase in patients with resistant acute myeloid leukemia. Blood. 96:2000;1517-1524
14. Mitchell B.S., Song J.J., Johnson E.E. II, Chen E., Dayton J.S. Regulation of human deoxycytidine kinase expression. Adv. Enzyme Regul. 33:1993;61-68
15. Hengstschlager M., Denk C., Wawra E. Cell cycle regulation of deoxycytidine kinase. Evidence for post-transcriptional control. FEBS Lett. 321:1993;237-240
16. Chen E.H., Johnson E.E. II, Vetter S.M., Mitchell B.S. Characterization of the deoxycytidine kinase promoter in human lymphoblast cell lines. J. Clin. Invest. 95:1995;1660-1668
17. Ives D.H., Durham J.P. Deoxycytidine kinase. III. Kinetics and allosteric regulation of the calf thymus enzyme. J. Biol. Chem. 245:1970;2285-2294
18. Datta N.S., Shewach D.S., Mitchell B.S., Fox I.H. Kinetic properties and inhibition of human T lymphoblast deoxycytidine kinase. J. Biol. Chem. 264:1989;9359-9364
19. Sasvari-Szekely M., Spasokoukotskaja T., Szoke M., Csapo Z., Turi A., Szanto I., et al. Activation of deoxycytidine kinase during inhibition of DNA synthesis by 2-chloro-2′-deoxyadenosine (Cladribine) in human lymphocytes. Biochem. Pharmacol. 56:1998;1175-1179
20. Spasokoukotskaja T., Sasvari-Szekely M., Keszler G., Albertioni F., Eriksson S., Staub M. Treatment of normal and malignant cells with nucleoside analogues and etoposide enhances deoxycytidine kinase activity. Eur. J. Cancer. 35:1999;1862-1867
21. Cardoen S., Van Den Neste E., Smal C., Rosier J.F., Delacauw A., Ferrant A., et al. Resistance to 2-chloro-2′-deoxyadenosine of the human B-cell leukemia cell line EHEB. Clin. Cancer Res. 7:2001;3559-3566
22. Csapo Z., Sasvari-Szekely M., Spasokoukotskaja T., Talianidis I., Eriksson S., Staub M. Activation of deoxycytidine kinase by inhibition of DNA synthesis in human lymphocytes. Biochem. Pharmacol. 61:2001;191-197
23. Van Den Neste E., Smal C., Cardoen S., Delacauw A., Frankard J., Ferrant A., et al. Activation of deoxycytidine kinase by UV-C-irradiation in chronic lymphocytic leukemia B-lymphocytes. Biochem. Pharmacol. 65:2003;573-580
24. Csapo Z., Keszler G., Safrany G., Spasokoukotskaja T., Talianidis I., Staub M., et al. Activation of deoxycytidine kinase by gamma-irradiation and inactivation by hyperosmotic shock in human lymphocytes. Biochem. Pharmacol. 65:2003;2031-2039
25. Smal C, Bertrand L, Van Den Neste E, Cardoen S, Veigha-da-Cunha M, Marie S, et al. New evidences for a regulation of deoxycytidine kinase activity by reversible phosphorylation. Nucleosides Nucleotides Nucleic Acids (in press).
26. Wang L.M., Kucera G.L. Deoxycytidine kinase is phosphorylated in vitro by protein kinase C alpha. Biochim. Biophys. Acta. 1224:1994;161-167
27. Spasokoukotskaja T., Csapo Z., Sasvari-Szekely M., Virga S., Talianidis I., Eriksson S., et al. Effect of phosphorylation on deoxycytidine kinase activity. Adv. Exp. Med. Biol. 486:2000;281-285
28. Smal C, Cardoen S, Van Den Neste E, Van den Berghe G, Bontemps F. Activation of deoxycytidine kinase by genistein. In: Eighth Symposium of European Society for the Study of Purine and Pyrimidine Metabolism in Man (ESSPPMM), 2001; Bruges, Belgium. p. 112.
29. Cohen P., Alemany S., Hemmings B.A., Resink T.J., Stralfors P., Lim Tung H.Y. Protein phosphatase-1 and protein phosphatase-2A from rabbit skeletal muscle. Methods Enzymol. 159:1988;390-408
30. Saltman D., Bansal N.S., Ross F.M., Ross J.A., Turner G., Guy K. Establishment of a karyotypically normal B-chronic lymphocytic leukemia cell line; evidence of leukemic origin by immunoglobulin gene rearrangement. Leuk. Res. 14:1990;381-387
31. Arner E.S., Spasokoukotskaja T., Eriksson S. Selective assays for thymidine kinase 1 and 2 and deoxycytidine kinase and their activities in extracts from human cells and tissues. Biochem. Biophys. Res. Commun. 188:1992;712-718
32. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254
33. Deprez J., Bertrand L., Alessi D.R., Krause U., Hue L., Rider M.H. Partial purification and characterization of a wortmannin-sensitive and insulin-stimulated protein kinase that activates heart 6-phosphofructo-2-kinase. Biochem. J. 347:2000;305-312
34. Sarkaria J.N., Tibbetts R.S., Busby E.C., Kennedy A.P., Hill D.E., Abraham R.T. Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. Cancer Res. 58:1998;4375-4382
35. Badwey J.A., Erickson R.W., Curnutte J.T. Staurosporine inhibits the soluble and membrane-bound protein tyrosine kinases of human neutrophils. Biochem. Biophys. Res. Commun. 178:1991;423-429
36. Spasokoukotskaja T, Keszler G, Sasvari-Szekely M, Virga S, Staub M. No effect of deoxycytidine kinase stimulating genotoxic agents on 5′-nucleotidases and dCMP deaminase. In: Eighth Symposium of European Society for the Study of Purine and Pyrimidine Metabolism in Man (ESSPPMM), 2001; Bruges, Belgium. p. 115.
37. Meydan N., Grunberger T., Dadi H., Shahar M., Arpaia E., Lapidot Z., et al. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature. 379:1996;645-648
38. Kirken R.A., Erwin R.A., Taub D., Murphy W.J., Behbod F., Wang L., et al. Tyrphostin AG-490 inhibits cytokine-mediated JAK3/STAT5a/b signal transduction and cellular proliferation of antigen-activated human T cells. J. Leuk. Biol. 65:1999;891-899
39. Gazit A., Yaish P., Gilon C., Levitzki A. Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors. J. Med. Chem. 32:1989;2344-2352
40. Akiyama T., Ishida J., Nakagawa S., Ogawara H., Watanabe S., Itoh N., et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem. 262:1987;5592-5595
41. Wang L.H., Kirken R.A., Erwin R.A., Yu C.R., Farrar W.L. JAK3, STAT, and MAPK signaling pathways as novel molecular targets for the tyrphostin AG-490 regulation of IL-2-mediated T cell response. J. Immunol. 162:1999;3897-3904
42. Abe J., Berk B.C. Fyn and JAK2 mediate Ras activation by reactive oxygen species. J. Biol. Chem. 274:1999;21003-21010
43. De Vos J., Jourdan M., Tarte K., Jasmin C., Klein B. JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells. Br. J. Haematol. 109:2000;823-828
44. Kim O.S., Park E.J., Joe E.H., Jou I. JAK-STAT signaling mediates gangliosides-induced inflammatory responses in brain microglial cells. J. Biol. Chem. 277:2002;40594-40601
45. Dudley D.T., Pang L., Decker S.J., Bridges A.J., Saltiel A.R. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc. Natl. Acad. Sci. USA. 92:1995;7686-7689
46. Favata M.F., Horiuchi K.Y., Manos E.J., Daulerio A.J., Stradley D.A., Feeser W.S., et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem. 273:1998;18623-18632
47. Favre B., Turowski P., Hemmings B.A. Differential inhibition and posttranslational modification of protein phosphatase 1 and 2A in MCF7 cells treated with calyculin-A, okadaic acid, and tautomycin. J. Biol. Chem. 272:1997;13856-13863
48. Yan Y., Mumby M.C. Distinct roles for PP1 and PP2A in phosphorylation of the retinoblastoma protein. PP2A regulates the activities of Gl cyclin-dependent kinases. J. Biol. Chem. 274:1999;31917-31924
49. Markovits J., Linassier C., Fosse P., Couprie J., Pierre J., Jacquemin-Sablon A., et al. Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II. Cancer Res. 49:1989;5111-5117
50. Janssens V., Goris J. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem. J. 353:2001;417-439